Life sciences briefing: Tuesday, Jan. 29, 2008
TODAY’S HEADLINES:
Immune-system specialty pharma Circassia raises £11M (release)
Cancer-biomarker biotech CS-Keys takes in $6.3M (release)
Neuro-robotic device maker Myomo receives $3M (VentureWire)
Micropharma draws C$1.8M for nutraceutical delivery (VentureWire)
Avalon Labs gets $66M for disposable life-support components (release)
Gloucester Pharma names Alan Colowick as CEO (release)
ConforMIS names Philipp Lang as CEO (release)
Pharma-marketing firm TargetRx names Craig Scott as CEO (release)
Immune-system specialty pharma Circassia raises £11M – Circassia, an Oxford, England biotech focused on immune-system disorders, raised £11 million ($21.8 million) in… Continue Reading
Life sciences briefing: Thursday, Nov. 8, 2007
Featured companies: Formac Pharmaceuticals, Pradama, Protein Sciences, SantoSolve, Scandius BioMedical
UPDATED: Expanded items on Protein Sciences, SantoSolve, Scandius and Pradama.
Vaccine maker Protein Sciences gets $1M — Protein Sciences, a Meriden, Conn., biotech working on a faster way to make flu vaccines, raised $1 million in a convertible-debt offering. Diamyd Medical, a Stockholm-based biotech focused on diabetes, provided the funding.
The funding boosts Diamyd’s total investment in Protein Sciences to $4 million. Conversion of its earlier investment made the Swedish… Continue Reading
BioVex raises $22M for cancer-killing viruses
Woburn, Mass.-based BioVex, a biotech working on new ways to attack cancer and infections, raised $22 million in a fifth funding round. Triathlon Medical Ventures led the round, joined by New Science Ventures, Forbion Capital Ventures, Avalon Ventures, Credit Agricole Private Equity, GeneChem Management, Innoven Partners and Scottish Equity Partners.
BioVex is developing so-called oncolytic viruses, which are designed to infect and destroy tumor cells — long a promising but never-proven anti-cancer technique. The company put… Continue Reading